Chevy Chase Trust Holdings LLC Has $73.85 Million Stake in Boston Scientific Corporation $BSX

Key Points

• Chevy Chase Trust trimmed its Boston Scientific stake by 3.2% to 756,423 shares worth $73.85 million, while other major investors (Norges Bank, Parnassus, Egerton, Jennison) markedly increased positions, leaving institutional ownership at 89.07%.
• CEO Michael F. Mahoney sold 160,901 shares on Feb. 2 for about $15.04 million, reducing his holding by 10.23%, and corporate insiders now own just 0.50% of the company.
• Boston Scientific is facing a filed class action over alleged misrepresentation of U.S. electrophysiology volumes, and multiple analysts have cut price targets; MarketBeat shows a consensus rating of "Moderate Buy" with an average target of $108.00.

Chevy Chase Trust Holdings LLC reduced its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 3.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 756,423 shares of the medical equipment provider's stock after selling 25,251 shares during the quarter. Chevy Chase Trust Holdings LLC owned 0.05% of Boston Scientific worth $73,850,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Norges Bank bought a new position in shares of Boston Scientific in the 2nd quarter valued at about $2,089,937,000. Edgewood Management LLC bought a new stake in shares of Boston Scientific in the 2nd quarter valued at about $746,655,000. Parnassus Investments LLC lifted its stake in Boston Scientific by 42,978.9% in the 3rd quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider's stock valued at $672,128,000 after purchasing an additional 6,868,459 shares during the last quarter. Egerton Capital UK LLP lifted its stake in Boston Scientific by 223.7% in the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider's stock valued at $518,660,000 after purchasing an additional 3,671,548 shares during the last quarter. Finally, Jennison Associates LLC grew its holdings in Boston Scientific by 133.5% during the third quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider's stock worth $482,170,000 after purchasing an additional 2,823,744 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

Insider Buying and Selling

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This trade represents a 10.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on BSX shares. Stifel Nicolaus lowered their price target on Boston Scientific from $125.00 to $110.00 and set a "buy" rating on the stock in a research report on Wednesday, February 4th. Mizuho reduced their target price on Boston Scientific from $140.00 to $115.00 and set an "outperform" rating for the company in a research note on Thursday, February 5th. Robert W. Baird decreased their target price on Boston Scientific from $118.00 to $101.00 and set an "outperform" rating on the stock in a report on Thursday, February 5th. National Bank Financial set a $115.00 price target on Boston Scientific in a research note on Monday, February 2nd. Finally, JPMorgan Chase & Co. cut their price target on Boston Scientific from $135.00 to $100.00 and set an "overweight" rating for the company in a report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $108.00.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Neutral Sentiment: Zacks published a recap explaining why Boston Scientific dipped more than the broader market, noting recent volatility around the company. Useful for context on short‑term market reaction. Article Title
• Negative Sentiment: Citigroup lowered its price target for Boston Scientific to $94.00 — a formal analyst downgrade that can weigh on sentiment and may lead some funds to reprice positions. Article Title
• Negative Sentiment: Levi & Korsinsky (reported via PR Newswire) and others say a filed class action alleges Boston Scientific executives misrepresented U.S. electrophysiology procedure volumes — this is the substantive allegation that could lead to discovery, potential damages or settlement risk. Investors should watch pleadings and any company response. Article Title
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Pomerantz, Glancy Prongay Wolke, Robbins Geller, Faruqi, Gross, Bernstein Liebhard, etc.) have issued shareholder alerts and deadline reminders (lead‑plaintiff motions due May 4, 2026). The coordinated outreach increases the likelihood of consolidated litigation and underscores ongoing legal scrutiny. Article Title

Boston Scientific Trading Up 0.9%

Shares of NYSE:BSX opened at $69.15 on Friday. Boston Scientific Corporation has a 12-month low of $67.56 and a 12-month high of $109.50. The stock has a market cap of $102.61 billion, a PE ratio of 35.64, a P/E/G ratio of 0.97 and a beta of 0.69. The business has a 50 day moving average of $82.47 and a 200-day moving average of $93.29. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts' consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm's quarterly revenue was up 15.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.